Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SFDA To Reappraise Safety Of TCM Injections

This article was originally published in PharmAsia News

Executive Summary

China's State FDA stated on its official website that the agency will soon start reappraising the safety of TCM injections nationwide in order to raise safety and quality standards and eliminate medicines with potential safety issues. SFDA has drawn up separate drafts on the key points of quality control and the primary requirements for TCM injection safety reappraisal. The documents are currently open to public feedback. TCM injection producers should actively conduct inspections to remove potential hazards in production and take measures to control risks. In addition, SFDA will carry out a survey of TCM injections' quality control. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts